title: Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified.
abstract: Cytotoxic molecules (CMs) are apoptosis-inducing molecules that are present in azurophilic cytoplasmic granules of T lymphocytes. Expression of TIA-1 and granzyme B was examined for 100 cases of nodal peripheral T-cell lymphoma, unspecified (PTCL-U) to assess clinicopathologic significance of CM. Forty-one were positive for at least one CM. Patients with CM-positive PTCL-U showed younger onset (median, 55 years vs. 64 years, P = 0.01) and less male predominance (male:female ratio, 21:20 vs. 44:15, P = 0.02). CM-positive PTCL-U was significantly associated with several clinical factors to indicate poor prognosis, in comparison with CM-negative PTCL-U, such as poorer performance status (P = 0.006), more frequent B-symptoms (68% vs. 35%, P = 0.002), higher serum lactate dehydrogenase levels (P = 0.003), and more frequent extranodal involvement, particularly bone marrow involvement (33% vs. 9%, P = 0.004). Epstein-Barr virus was mostly found in CM-positive PTCL-U (51% vs. 2%, P < 0.0001). The CM-positive group showed higher distribution of the International Prognostic Index (P = 0.009) and the Prognostic Index for T-cell lymphoma (P = 0.004) scores than CM-negative group. Complete remission rate was 30% for the former but 63% for the latter. Overall survival of CM-positive PTCL-U was significantly lower than that of CM-negative patients (P = 0.004). Multivariate analyses confirmed that CM expression is a significant prognostic factor, independent from other clinical factors or prognostic index scores. These findings suggest that nodal CM-positive PTCL-U show distinct clinicopathologic characteristics among the current category of PTCL-U.
authors.affiliation: Department of Pathology and Molecular Diagnostics, Division of Molecular Medicine, Aichi Cancer Center, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Asano
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Yoshitoyo
authors.initials: Y
authors.lastname: Kagami
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Ishida
authors.forename: Kunio
authors.initials: K
authors.lastname: Kitamura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Fukutani
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D053804:Granzymes; D006801:Humans; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D002479:Inclusion Bodies / Q000378:metabolism; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016601:RNA-Binding Proteins / Q000096:biosynthesis*; D012697:Serine Endopeptidases / Q000096:biosynthesis*; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; D016601:RNA-Binding Proteins; C076751:TIAL1 protein, human; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases